Perennial Advisors’s Crescent Biopharma CBIO Stock Holding History

Perennial Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-10	Closed	-$2K	–	150
2021 Q2	$2K	Hold	10	–	–	﹤0.01%	284
2021 Q1	$3K	Hold	10	–	–	﹤0.01%	274
2020 Q4	$4K	Buy	+10	New	+$3.5K	﹤0.01%	230
2020 Q3	–	Sell	-10	Closed	-$4K	–	129
2020 Q2	$4K	Buy	+10	New	+$2.83K	﹤0.01%	206
2019 Q1	–	Sell	-10	Closed	-$9K	–	122
2018 Q4	$9K	Hold	10	–	–	0.01%	168
2018 Q3	$14K	Hold	10	–	–	0.01%	157
2018 Q2	$16K	Hold	10	–	–	0.01%	150
2018 Q1	$16K	Hold	10	–	–	0.01%	147
2017 Q4	$17K	Sell	10 -5	-33%	-$6.61K	0.01%	156
2017 Q3	$21K	Hold	15	–	–	0.01%	133
2017 Q2	$17K	Hold	15	–	–	0.01%	138
2017 Q1	$8K	Hold	15	–	–	0.01%	157
2016 Q4	$9K	Buy	+15	New	+$9.36K	0.01%	168

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Perennial Advisors's CBIO Position: Q3 2021 in Review

Perennial Advisors sold out of Crescent Biopharma (CBIO) in Q3 2021, closing a stake of 10 shares — an estimated $2K sold.

Perennial Advisors first reported a position in CBIO in Q4 2016 and held it in 13 quarters. The position peaked at $21K in Q3 2017. 47 funds tracked by Wall St. Rank hold CBIO as of Q3 2021.

Perennial Advisors reported no remaining Crescent Biopharma position as of Q3 2021 after selling out during the quarter.
Perennial Advisors sold 10 Crescent Biopharma shares in Q3 2021, an estimated $2K.
Perennial Advisors first reported a position in Crescent Biopharma in Q4 2016 and held it in 13 quarters.
Perennial Advisors's Crescent Biopharma position peaked at $21K in Q3 2017.
47 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2021.

Based on Perennial Advisors's 13F filing for Q3 2021, filed 8 Nov 2021.